JULIO BELARMINO
BOBES GARCIA
Chercheur jusqu' 2022
Instituto de Neurociencias del Principado de Asturias
Oviedo, EspañaPublications en collaboration avec des chercheurs de Instituto de Neurociencias del Principado de Asturias (18)
2024
-
Clinical predictors and psychosocial risk factors of suicide attempt severity
Spanish Journal of Psychiatry and Mental Health
-
The mediating role of reflective functioning in the association between childhood trauma and suicide attempt
Journal of Psychiatric Research, Vol. 171, pp. 30-37
2023
-
Common genetic variants contribute to heritability of age at onset of schizophrenia
Translational Psychiatry, Vol. 13, Núm. 1
-
Correction: Common genetic variants contribute to heritability of age at onset of schizophrenia (Translational Psychiatry, (2023), 13, 1, (201), 10.1038/s41398-023-02508-0)
Translational Psychiatry
-
Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio in depressed patients with suicidal behavior: A systematic review
European Psychiatry
2020
-
COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?
Schizophrenia Research, Vol. 223, pp. 192-198
-
Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences
Scientific Reports, Vol. 10, Núm. 1
-
Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample
Journal of global health, Vol. 10, Núm. 2, pp. 020505
-
Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model
European Neuropsychopharmacology, Vol. 33, pp. 158-163
-
Prevalence of Passive Suicidal Ideation in the Early Stage of the Coronavirus Disease 2019 (COVID-19) Pandemic and Lockdown in a Large Spanish Sample
The Journal of clinical psychiatry, Vol. 81, Núm. 6
-
Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene
Schizophrenia Research
2019
-
Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?
Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 9-16
-
Early versus late stage schizophrenia. What markers make the difference?
World Journal of Biological Psychiatry, Vol. 20, Núm. 2, pp. 159-165
-
History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders
European Addiction Research, Vol. 25, Núm. 3, pp. 111-118
-
Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology
Psychiatry Research, Vol. 280
2018
-
Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia
Psychiatry Research, Vol. 269, pp. 688-691
-
Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls
European Psychiatry, Vol. 47, pp. 50-59
2016
-
Biomarcadores sanguíneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia
Revista de Psiquiatria y Salud Mental